Di Zhou

Di Zhou

Auto-generated profile, based on publicly available information

Di Zhou

Department of Phase I Clinical Trials Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China; Anhui Provincial Key Laboratory of Precision Pharmaceutical Preparations and Clinical Pharmacy, Hefei, Anhui, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2025 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
DZDi Zhou
Di Zhou
XCXinyi Chen
Xinyi Chen
MJMeng Jia
Meng Jia
XLXiaoxiao Liu
Xiaoxiao Liu
LHLingzhi Huang
Lingzhi Huang
LTLiqin Tang
Liqin Tang
Ferroptosis, an iron-dependent form of cell death characterized by lipid peroxidation, has been recognized as a critical mechanism contributing to podocyte injury in diabetic kidney disease (DKD). Although interferon-stimulated gene 20 (ISG20) has been identified as a novel regulator of RNA oxidation stress in acute kidney disease, its specific role and mechanism in DKD remain to be elucidated. In this study, we investigated the role of ISG20 in ferroptosis and its potential as a therapeutic target in DKD. We found that ISG20-deficient mice exhibited excessive iron accumulation, increased lipid peroxidation, and markedly higher proteinuria compared to wild-type mice. Nevertheless, the administration of a ferroptosis inhibitor, ferrostatin-1(Fer-1), mitigated kidney injury. Consistent results were observed in vitro, where the detrimental effects of ISG20 gene silencing could be mitigated by Fer-1 treatment in mouse podocytes under high glucose (HG) conditions. To further investigate the protective effects of ISG20, we administered two distinct vectors into diabetic mice: an adenovirus vector overexpressing ISG20 and a novel mRNA-loaded lipid nanoparticle (LNP) therapeutic vector expressing ISG20 mRNA. Both approaches effectively mitigated podocyte ferroptosis, alleviated podocyte injury, and reduced proteinuria in DKD. Similar results were also found in mice with adriamycin-induced nephropathy. Overall, this study establishes that ISG20 safeguards podocyte viability by suppressing ferroptosis, which extends ISG20’s biological role. These findings suggest that ISG20 may be a potential therapeutic strategy for treating patients with proteinuric kidney disease.

27 April 2026 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
DZDi Zhou
Di Zhou
YLYinxia Li
Yinxia Li
LNLijuan Ning
Lijuan Ning
YWYue Wang
Yue Wang
HQHuijuan Qu
Huijuan Qu
ZYZhaoyi Yang
Zhaoyi Yang